What it's for (Indications)
- Brimonidine tartrate ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Its therapeutic efficacy stems from its ability to lower IOP, thereby reducing the risk of optic nerve damage and subsequent visual field loss associated with these conditions.
- It is frequently employed as monotherapy or as an adjunctive treatment when other IOP-lowering medications are insufficient.
- The long-term safety and efficacy profile supports its use in appropriate patient populations requiring sustained IOP reduction to preserve visual function and prevent disease progression.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for brimonidine tartrate ophthalmic solution typically involves instilling one drop into the affected eye(s) two or three times daily, depending on the specific concentration and formulation (e.g., 0.1%, 0.15%, 0.2%). For optimal absorption and to minimize potential washout, patients should wait at least 5 minutes between administering brimonidine tartrate and other topical ophthalmic medications. It is crucial for patients to be instructed on the correct instillation technique to ensure proper dosing and to avoid contamination of the dropper tip. Adherence to the prescribed dosing regimen is essential for achieving and maintaining adequate intraocular pressure control. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse reactions associated with brimonidine tartrate ophthalmic solution include ocular hyperemia (redness), burning or stinging upon instillation, blurred vision, allergic conjunctivitis, follicular conjunctivitis, and ocular pruritus.
- Systemic side effects may include dry mouth, headache, and somnolence.
- Less frequently observed, but potentially more serious, adverse events can encompass localized allergic reactions, dizziness, bradycardia, hypotension, and symptoms indicative of central nervous system depression such as fatigue and asthenia.
- Patients should be advised to report any persistent or severe adverse effects to their healthcare provider.
Serious Warnings
- Black Box Warning: Brimonidine tartrate ophthalmic solution does not carry a formal FDA Black Box Warning. However, it is essential to highlight critical safety information, particularly concerning pediatric use, as a **SERIOUS WARNING**: **SERIOUS WARNINGS: PEDIATRIC RISK AND SYSTEMIC EFFECTS** Brimonidine tartrate ophthalmic solution is **not recommended and is contraindicated** for use in children under the age of 2 years. Postmarketing surveillance and clinical reports have documented severe and potentially life-threatening systemic adverse reactions in infants and neonates exposed to brimonidine, including apnea, bradycardia, hypotension, hypothermia, cyanosis, and profound somnolence. These effects are attributed to systemic absorption and subsequent central nervous system depression. Healthcare providers must exercise extreme caution when considering its use in children, and generally, alternative therapies are preferred for pediatric patients under two years of age due to this significant safety concern. Close monitoring of vital signs and neurological status is imperative if accidental exposure or off-label use occurs in this vulnerable population. Additionally, systemic absorption of brimonidine can lead to cardiovascular effects (e.g., orthostatic hypotension, bradycardia) and central nervous system depression (e.g., somnolence, fatigue, dizziness). Patients should be warned about operating hazardous machinery or driving if they experience these symptoms. Caution is advised in patients with severe cardiovascular disease or depression, and co-administration with other CNS depressants or MAO inhibitors (which is contraindicated) requires careful consideration.
- Brimonidine tartrate should be used with caution in patients with severe cardiovascular disease, including those with cardiac insufficiency, unstable angina, recent myocardial infarction, uncontrolled hypertension, or a history of stroke, due to the potential for systemic absorption leading to blood pressure and heart rate changes.
- Caution is also advised in patients with depression.
- Systemic absorption can result in central nervous system (CNS) depression, manifesting as somnolence and fatigue, which may impair the ability to operate machinery or drive; these effects can be potentiated by alcohol, sedatives, hypnotics, opioids, or other CNS depressants.
- Contact lenses should be removed prior to instillation and reinserted at least 15 minutes later to prevent absorption of the preservative.
- Delayed ocular hypersensitivity reactions have been reported, necessitating discontinuation if observed.
How it Works (Mechanism of Action)
Brimonidine tartrate functions as a relatively selective alpha-2 adrenergic receptor agonist. Its primary mechanism of action in reducing elevated intraocular pressure involves decreasing the production of aqueous humor, the fluid within the eye. This effect is achieved through activation of alpha-2 receptors on the ciliary body, leading to vasoconstriction and a subsequent reduction in blood flow to the ciliary processes, where aqueous humor is formed. Additionally, some studies suggest a minor contribution from an increase in uveoscleral outflow. The overall result is a significant and sustained reduction in intraocular pressure, which is critical for managing glaucoma and ocular hypertension.
Commercial Brands (Alternatives)
No other brands found for this formula.